Trial reportJournal of translational medicine2007
Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis.
Trial report in Journal of translational medicine, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01163799 (A Pilot Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients), which is not on this map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pilot Study to Assess the Safety and Efficacy of Alefacept in de Novo Kidney Transplant Recipients
Who cites it
41 citing papers in PubMed, 71 citations in OpenAlex.
- Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.The Journal of clinical investigation · 2015Trial
- Targeting of memory T cells with alefacept in new-onset type 1 diabetes (T1DAL study): 12 month results of a randomised, double-blind, placebo-controlled phase 2 trial.The lancet. Diabetes & endocrinology · 2013Trial
- Personalized medicine in psoriasis: developing a genomic classifier to predict histological response to Alefacept.BMC dermatology · 2010Trial
- Study on the synthesis, physicochemical properties and transdermal absorption of scutellarein prodrugs.Scientific reports · 2025Article
- Article
- Early expansion of TIGIT+PD1+ effector memory CD4 T cells via agonistic effect of alefacept in new-onset type 1 diabetes.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Sequential immunotherapy: towards cures for autoimmunity.Nature reviews. Drug discovery · 2024Review
- Bibliometric analysis and description of research trends on T cells in psoriasis over the past two decades (2003-2022).Heliyon · 2024Article
- Research Advances in Fusion Protein-Based Drugs for Diabetes Treatment.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024Review
- Discovery of PANoptosis-related signatures correlates with immune cell infiltration in psoriasis.PloS one · 2024Article
- Shifting the paradigm of type 1 diabetes: a narrative review of disease modifying therapies.Frontiers in endocrinology · 2024Review
- miR-4759 suppresses breast cancer through immune checkpoint blockade.Computational and structural biotechnology journal · 2022Article
- Article
- Article
- The Role of Co-Signaling Molecules in Psoriasis and Their Implications for Targeted Treatment.Frontiers in pharmacology · 2021Review
- Transcriptome-Based Molecular Networks Uncovered Interplay Between Druggable Genes of CD8Frontiers in medicine · 2021Article
- CD58 Immunobiology at a Glance.Frontiers in immunology · 2021Review
- Memory T Cells in Transplantation: Old Challenges Define New Directions.Transplantation · 2020Review
- Costimulatory Function of Cd58/Cd2 Interaction in Adaptive Humoral Immunity in a Zebrafish Model.Frontiers in immunology · 2018Article
- Potential Immunological Links Between Psoriasis and Cardiovascular Disease.Frontiers in immunology · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
backgroundAlefacept (anti-CD2) biological therapy selectively targets effector memory T cells (Tem) in psoriasis vulgaris, a model Type 1 autoimmune disease.
methodsCirculating leukocytes were phenotyped in patients receiving alefacept for moderate to severe psoriasis.
resultsIn all patients, this treatment caused a preferential decrease in effector memory T cells (CCR7- CD45RA-) (mean 63% reduction) for both CD4+ and CD8+ Tem, while central memory T cells (Tcm) (CCR7+CD45RA-) were less affected, and naïve T cells (CCR7+CD45RA+) were relatively spared. Circulating CD8+ effector T cells and Type 1 T cells (IFN-gamma-producing) were also significantly reduced.
conclusionAlefacept causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.